Morgan Bron, PharmD, MS

Neurocrine Biosciences, Inc., San Diego, California

  • 2Articles
  • 13.7KReads
  • 2023–2026Active
  • 17Collaborators
  • 6Citations

About

Morgan Bron, PharmD, MS is affiliated with Neurocrine Biosciences, Inc., San Diego, California. Morgan Bron has authored or co-authored 2 peer-reviewed articles published across the Journal of Clinical Psychiatry and the Primary Care Companion for CNS Disorders between 2023 and 2026. Their work focuses on Movement Disorders, Schizophrenia/Schizoaffective Disorders, and Tardive Dyskinesia.

Publications

JCP
Validation for the Tardive Dyskinesia Impact Scale, a Patient-Reported Outcome Measure in Valbenazine Clinical Trials
Narrative Review

Validation for the Tardive Dyskinesia Impact Scale, a Patient-Reported Outcome Measure in Valbenazine Clinical Trials

April 29, 2026

The TDIS followed a similar trajectory to other clinician- and patient-reported outcomes measured in tardive dyskinesia clinical trials, and a change of 4 points in total score is considered...
, , , et al
PCC
Benztropine Usage Patterns in Movement Disorders
Original Research

Benztropine Usage Patterns in Movement Disorders

August 29, 2023

This study evaluated real-world treatment patterns for patients initiating benztropine and examined treatment approaches in patients with drug-induced movement disorders from a health care provider perspective.
, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe